Adverse Pregnancy Outcomes With Isoniazid Preventive Therapy in HIV

Published Date:

03/09/2018

Publication:

Infectious Disease Advisor

Isoniazid preventive therapy (IPT) for tuberculosis in pregnant women with HIV was associated with excess adverse pregnancy outcomes and may warrant a reassessment of the current World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines, according to a poster presented at CROI 2018, held from March 4-7 in Boston, Massachusetts.

Access Full Article

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More